| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
27,533 |
23,520 |
$931K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,808 |
13,789 |
$737K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
16,418 |
14,747 |
$603K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
33,141 |
14,836 |
$414K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,529 |
4,368 |
$323K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
19,317 |
16,904 |
$242K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,190 |
2,997 |
$228K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,833 |
2,736 |
$213K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
18,877 |
8,160 |
$191K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,614 |
2,165 |
$112K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
15,893 |
14,413 |
$95K |
| 99429 |
|
2,025 |
1,985 |
$65K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
860 |
828 |
$65K |
| 87634 |
|
1,224 |
1,116 |
$61K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
8,964 |
7,147 |
$56K |
| 87807 |
|
4,056 |
3,634 |
$41K |
| 90461 |
|
11,812 |
4,398 |
$29K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
679 |
623 |
$28K |
| 99000 |
|
3,457 |
3,109 |
$26K |
| 83655 |
|
626 |
604 |
$6K |
| 92558 |
|
766 |
740 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
571 |
460 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
405 |
354 |
$4K |
| 81002 |
|
1,293 |
1,150 |
$3K |
| 86769 |
|
92 |
38 |
$3K |
| 92552 |
|
341 |
332 |
$2K |
| 99381 |
|
39 |
37 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
137 |
83 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
140 |
88 |
$1K |
| 0071A |
|
33 |
31 |
$1K |
| 99215 |
Prolong outpt/office vis |
19 |
14 |
$1K |
| 0072A |
|
30 |
30 |
$1K |
| 0001A |
|
49 |
48 |
$930.02 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13 |
13 |
$848.25 |
| 36410 |
|
44 |
42 |
$589.20 |
| 0111A |
|
15 |
15 |
$520.00 |
| 96160 |
|
1,125 |
1,080 |
$460.73 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
17 |
17 |
$446.18 |
| 90677 |
|
487 |
481 |
$254.76 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
42 |
19 |
$200.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
12 |
12 |
$187.68 |
| 99050 |
|
14 |
14 |
$137.54 |
| 99051 |
|
222 |
209 |
$136.50 |
| 90686 |
|
1,868 |
1,804 |
$40.05 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
417 |
355 |
$24.50 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
55 |
27 |
$21.12 |
| 36416 |
|
7,354 |
6,555 |
$3.50 |
| 90656 |
|
271 |
270 |
$0.01 |
| 90633 |
|
800 |
767 |
$0.00 |
| 90670 |
|
1,876 |
1,804 |
$0.00 |
| 90648 |
|
1,578 |
1,528 |
$0.00 |
| 90685 |
|
620 |
609 |
$0.00 |
| 90681 |
|
675 |
661 |
$0.00 |
| 99177 |
|
467 |
451 |
$0.00 |
| 90707 |
|
94 |
90 |
$0.00 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
19 |
17 |
$0.00 |
| 90700 |
|
110 |
108 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
25 |
24 |
$0.00 |
| 99173 |
|
118 |
115 |
$0.00 |
| 91311 |
|
12 |
12 |
$0.00 |
| 90734 |
|
26 |
25 |
$0.00 |
| 90710 |
|
44 |
42 |
$0.00 |
| T1015 |
Clinic visit/encounter, all-inclusive |
54 |
52 |
$0.00 |
| 90698 |
|
38 |
38 |
$0.00 |
| 90716 |
|
94 |
89 |
$0.00 |
| 90723 |
|
964 |
938 |
$0.00 |
| 90696 |
|
32 |
30 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
173 |
163 |
$0.00 |
| 90651 |
|
36 |
36 |
$0.00 |
| 90647 |
|
75 |
73 |
$0.00 |
| 96127 |
|
115 |
71 |
$0.00 |